Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-15. (Canceled)

16. (Currently amended) A method for treating haemolytic disease of the newborn, Sezary Syndrome, chronic myeloid leukaemias, chronic lymphoid leukaemias (CLL-B), cancer, breast cancer, conditions related to the environment ~~in particular affecting people exposed to polychlorinated biphenyls~~, infectious diseases, ~~in particular tuberculosis,~~ chronic fatigue syndrome (CFS), parasitic infections ~~including schistosomas or paludism, in particular in pregnant women~~, and viral infections, comprising administering a composition of antibodies wherein said antibodies are over 60%, ~~preferably over 80%,~~ for the forms G0 + G1 + G0F + G1F, given that the forms G0F + G1F are lower than 50%, ~~preferably lower than 30%,~~ to patients homozygous for phenylalanine in position 158 of CD16 (FCGR3A-158F homozygotes) or patients heterozygous for valine/pheynylalanine in position 158 of CD16 (FCGR3A-158V/F).

17. (Canceled)

18. (Currently amended) The method according to claim 16, wherein the dose of said antibody administered to the patient is 50 times lower~~, preferably 100 times lower~~ than a dose of an antibody of the same specificity but of different glycosylation or produced in a CHO line.

19. (Previously Presented) The method according to claim 16, wherein that the antibody is directed against a non-ubiquitous antigen present in healthy donor cells, ~~in particular an anti-Rhesus of the human red blood cell,~~ or an antigen of a pathological cell or of an organism pathogenic for humans~~, in particular against an antigen of a cancer cell or infected by a virus~~.

20. (Previously Presented) The method according to claim 16 for treating cancers of positive HLA class-II cells, B-cell lymphomas, acute B-cell leukaemias, Burkitt's

syndrome, Hodgkin's lymphoma, myeloid leukaemias, chronic B-cell lymphoid leukaemias (CLL-B), non-Hodgkin's T-cell leukaemias and lymphomas and chronic myeloid leukaemias.

21. (Previously Presented) The method according to claim 16, wherein the antibody is anti-HLA-DR.

22. (Previously Presented) The method according to claim 16, wherein the antibody is anti-CD20.

23. (Currently Amended) The method according to claim 15, wherein the antibody ~~is characterised in that the antibody~~ is selected from the group consisting of anti-HLA-DR, anti-CD20, anti Ep-CAM, anti HER2, anti CD52, anti HER1, anti GD3, anti CA125, anti GD, anti GD2, anti CD-23 and anti Protein C_1[[;]] anti-KIR3DL2, anti-EGFR, anti-CD25, anti-CD38, anti-CD30, anti-CD33, anti-CD44, ~~inhibitor-specific anti-idiotypes, for example, coagulation factors~~, and anti-viral antibodies ~~anti virals~~.

24. (Currently Amended) The method according to claim 16, wherein the antibody ~~is characterised in that the antibody~~ is selected from the group consisting of anti-HLA-DR, anti-CD20, anti EP-CAM, anti HER2, anti CD52, anti HER1, anti GD3, anti CA125, anti GD, anti GD2, anti CD-23 and anti Protein C_1[[;]] anti-KIR3DL2, anti-EGFR, anti-CD25, anti-CD38, anti-CD30, anti-CD33, anti-CD44 ~~inhibitor-specific anti-idiotypes, for example, coagulation factors~~, and anti-viral antibodies ~~anti virals~~.